The U.S. Pain Foundation recently submitted comments to the Food and Drug Administration (FDA) in response to its request for Guidance for Industry Comments to the Docket regarding the Development of Non-Opioid Analgesics for Acute Pain.
- U.S. Pain Foundation’s Docket Comments to the FDA on the Development of Non-Opioid Analgesics for Acute Pain
- U.S. Pain Foundation’s Comments on the 2022 Revised Draft CDC Clinical Practice Guideline for Prescribing Opioids
- U.S. Pain Foundation launches 2022 Chronic Pain Community Survey
- Preparing for the Expected Aging Process
- Storm of Pain